

Claims

1. Use of HC gp-39 or fragments thereof for the manufacture of a pharmaceutical preparation for modulation of the reactivity of lymphocytes, said lymphocytes
5 being reactive to antigens other than HC gp-39, said antigens being present in the same tissue as HC gp-39 so as to prevent inflammatory diseases.
2. Use of fragments according to claim 1 characterized in that the fragments are selected from the group comprising an amino acid sequence given in SEQ ID NO:1 (FGRSFTLAS), SEQ ID NO:2 (FTLASSETG), SEQ ID NO:3
10 (YDDQESVKS), SEQ ID NO:4 (FSKIASNTQ), SEQ ID NO:5 (PTFGRSFTLASSE, SEQ ID NO:6 (RSFTLASSETGVG), SEQ ID NO:7 (VGYDDQESVSKSV) or SEQ ID NO:8 (SQRFSKIASNTQSR).
3. Use of HC gp-39 or fragments thereof according to claims 1 or 2 for the manufacture of a pharmaceutical preparation for modulation of the reactivity of
15 lymphocytes, said lymphocytes being reactive to antigens other than HC gp-39, said antigens being present in the same tissue as HC gp-39 so as to prevent rheumatoid arthritis.